Rank 34 • Biotech & Discovery
Exscientia
Applies an end-to-end AI platform to discover and design precision medicines for oncology and immunology.
Visit website- Signal Score
- 88.4
- Total raised
- $500M
- Stage
- Public
- Founded
- 2012
- Headquarters
- Oxford, UK
- Region
- Europe
Their signal
Exscientia's AI-designed molecules were among the first to enter clinical trials. Its automated, patient-first approach to testing ex vivo tissues sets a high benchmark for precision oncology discovery.
Signal Score 88.4editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Did we miss something?
Change, add or remove details on this company. Our desk reviews every request.
Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.